How Investors Assess R&D Biotech Management

At the May 2015 Chief Medical Officer's Summit in Boston, we featured a session on:

How Investors Assess R&D Biotech Management
Take a look at the details below:
In this session, we begin with a presentation on a perspective on the method of evaluating a disease space, which includes a comprehensive understanding of 1) the science, 2) the competitive landscape and 3) the management teams for each company. How does this get mapped out?
Following will be more discussion on:
Understanding the context of value proposition
Strategic fit
Processes used to evaluate management and an understanding of competitive strategy
How best to convey your plans
How best to communicate with investors (before investment) and boards (afterwards) – via the CEO or directly?
Importance of clinical development plan expectations
Moderated by: Peter Kolchinsky, PhD Managing Director, RA Capital Management, LLC
Panelists: Jonathan Behr, PhD EIR and Market Sector Leader, Innovation, Partners Healthcare, David Berry, MD, PhD Partner, Flagship Ventures, Vikas Goyal, MBA Principal, SR One, and Jeffrey Moore, DPhil, MBA President, MPH Venture Management
The next CMO Summit is November 9-10 in Burlingame, California. It is one of the best face-to-face opportunities for R&D leaders in emerging biotechs to:
1. Address the unique challenges associated with directing and managing all R&D functions with limited resources, while raising capital, working and meeting with investors, and strategizing for appropriate exits. 2. To create a network of CMOs & other R&D leaders from small to midsize life science companies to share ideas, solutions and support.

For information, visit www.theconferenceforum.org

Partial and full scholarships available for start-ups.